Company Overview and News

1
RDNT / RadNet, Inc. FORM 8-K (Current Report)

2018-06-11 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
RDNT

1
RadNet, Inc. to Present at the 8th Annual LD Micro Invitational on June 6th

2018-06-04 globenewswire
LOS ANGELES, June 04, 2018 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the 8th Annual LD Micro Invitational Conference in Los Angeles on Wednesday, June 6, 2018 at 08:00 a.
RDNT

1
RadNet, Inc. to Present at the Jefferies 2018 Healthcare Conference on June 7, 2018

2018-06-04 globenewswire
LOS ANGELES, June 04, 2018 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Dr. Howard Berger, President and Chief Executive Officer, will be presenting at the Jefferies 2018 Global Healthcare Conference in New York, NY on Thursday, June 7, 2018 at 1:30 p.
RDNT

1
RadNet, Inc. to Present at the Bank of America Merrill Lynch 2018 Health Care Conference on May 17th, 2018

2018-05-15 globenewswire
LOS ANGELES, May 15, 2018 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer will be presenting at the Bank of America Merrill Lynch 2018 Health Care Conference in Las Vegas, NV on Thursday, May 17, 2018 at 09:20 a.
RDNT

6
RDNT / RadNet, Inc. FORM 10-Q (Quarterly Report)

2018-05-10 sec.gov
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549
RDNT

1
RDNT / RadNet, Inc. FORM 8-K (Current Report)

2018-05-10 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
RDNT

1
RadNet Reports First Quarter Financial Results

2018-05-09 globenewswire
LOS ANGELES, May 09, 2018 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 300 owned and/or operated outpatient imaging centers, today reported financial results for its first quarter of 2018.
RDNT

1
RadNet, Inc. Announces Date of its First Quarter 2018 Financial Results Conference Call

2018-05-02 globenewswire
LOS ANGELES, May 02, 2018 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced today that it will host a conference call to discuss its first quarter 2018 financial results on Wednesday, May 9th, 2018 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).
RDNT

3
RDNT / RadNet, Inc. DEF 14A

2018-04-27 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A
RDNT

1
How RadNet (RDNT) Stock Stands Out in a Strong Industry

2018-04-06 zacks
One stock that might be an intriguing choice for investors right now is RadNet, Inc. (RDNT - Free Report) . This is because this security in the Medical - Outpatient and Home Healthcare space is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective. This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board.
RDNT KEP NAP

7
Can The Uptrend Continue for RadNet (RDNT)?

2018-03-26 zacks
Investors certainly have to be happy with RadNet, Inc. (RDNT - Free Report) and its short term performance. After all, the stock has jumped by 34.7% in the past 4 weeks, and it is also above its 20 Day Simple Moving Average as well. This is certainly a good trend, but investors are probably asking themselves, can this positive trend continue for RDNT?
RDNT WTR AFH

4
RDNT / RadNet, Inc. FORM 10-K (Annual Report)

2018-03-19 sec.gov
Table of Contents UNITED STATES
RDNT

6
RDNT / RadNet, Inc. FORM 8-K (Current Report)

2018-03-15 sec.gov
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
RDNT

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: 750491102